Nektar Therapeutics Statement regarding PureTech Health plc (4133C)
October 11 2022 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 4133C
Nektar Therapeutics
11 October 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH
JURISDICTION.
THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE
ON TAKEOVERS AND MERGERS (THE "CODE")
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR IMMEDIATE RELEASE
11 October 2022
Nektar Therapeutics ("Nektar")
Rule 2.8 Announcement
Further to the announcement made by PureTech Health plc ("
PureTech ") on 7 October 2022, Nektar announces that it has
mutually agreed with PureTech to terminate discussions regarding a
potential business combination.
Important Code notes
This is a statement to which Rule 2.8 of the Code applies.
As is customary under Rule 2.8 of the Code, Nektar reserves the
right to make or participate in an offer for PureTech (and/or take
any other actions which would otherwise be restricted under Rule
2.8 of the Takeover Code) within the next six months following the
date of this announcement:
i. with the agreement of the PureTech Board;
ii. following the announcement of a firm intention to make an
offer for PureTech by or on behalf of a third party;
iii. following the announcement by PureTech of a Rule 9 waiver
proposal (as described in Note 1 of the Notes on Dispensations from
Rule 9 of the Takeover Code) or a reverse takeover (as defined in
the Code); or
iv. where the Takeover Panel has determined that there has been
a material change of circumstances.
For the purposes of UK MAR, the person responsible for arranging
release of this announcement on behalf of Nektar is Jennifer
Ruddock.
Enquiries:
Nektar Therapeutics
Jennifer Ruddock
415-482-5585
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
OUPGPGUWUUPPPWU
(END) Dow Jones Newswires
October 11, 2022 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024